Featured Editorial
2018 Biosimilar Triumphs And Tribulations: How Have Market Expectations Evolved?
 
By Anna Rose Welch, editor, Biosimilar Development

In the first part of a three-part “Ask The Board” series, members of the Biosimilar Development editorial board share what left them feeling the most heartened or concerned in 2018, and what must take center stage as we head into 2019.

An Inside Look: The Oncologist’s Perspective On Biosimilars
 
A conversation with Lee S. Schwartzberg, M.D., West Cancer Center

In this Q&A, Dr. Schwartzberg discusses his own experience with biosimilars, some of the biggest stumbling blocks in the clinical setting for biosimilar integration, and the most overlooked stakeholders in education strategies.

Express Scripts New Flex Formulary: Biosimilar Friend Or Foe?
 
By Anna Rose Welch, editor, Biosimilar Development

Though it’s much too early to say for sure, we will need to watch how this formulary impacts the brand vs. biosimilar landscape, and, in turn, the performance of biosimilars in the pharmacy reimbursement space.

Industry Insights
Is Selecting A CDMO Based On Contract Price Really Saving You Money In The Long Run?
Article | By Dorene Lynch, Pfizer CentreOne Contract Manufacturing

Before you sign on the dotted line, do a little digging to unearth potential costs that could turn your development program into a cash-burning exercise.

Designing A Biomanufacturing Facility Incorporating Single-Use Technologies
Article | GE Healthcare Life Sciences

When building a new facility based on single-use technologies, or incorporating single-use into an existing facility, how do companies ensure they fully realize the benefits?

Connect With Biosimilar Development:
      Twitter